鱼腥草注射液联合利奈唑胺治疗耐甲氧西林金黄色葡萄球菌感染肺炎的临床研究

目的探讨鱼腥草注射液联合利奈唑胺治疗耐甲氧西林金黄色葡萄球菌(MRSA)感染肺炎的临床疗效。方法选取2014年5月—2016年5月在郑州市第六人民医院接受治疗的78例MRSA感染肺炎患者为研究对象,根据用药方案的不同分为对照组(39例)和治疗组(39例)。对照组静脉注射利奈唑胺注射液,600 mg/次,2次/d。治疗组在对照组的基础上静脉滴注鱼腥草注射液,100 m L加入5%葡萄糖溶液500 m L,1次/d。两组均治疗2周。评价两组患者临床疗效,同时比较治疗前后两组患者MRSA清除率、临床症状缓解时间和血清学指标的变化。结果治疗后,对照组和治疗组的总有效率分别为79.49%、94.87%,两组比较差异具有统计学意义(P0.05)。对照组和治疗组的MRSA清除率分别为74.36%、92.31%,两组MRSA清除率比较差异具有统计学意义(P0.05)。治疗后,治疗组的体温恢复正常时间、咳嗽咳痰缓解时间、胸闷、气促缓解时间明显短于对照组,两组比较差异具有统计学意义(P0.05)。两组C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、降钙素(PCT)、总氧化态(TOS)水平明显降低,而总抗氧化态(TAS)和对氧磷酶1(PON1)水平明升高,同组治疗前后差异有统计学意义(P0.05);且治疗组的血清学指标改善程度优于对照组,两组比较差异具有统计学意义(P0.05)。结论鱼腥草注射液联合利奈唑胺治疗MRSA感染肺炎效果显著,可有效改善患者临床症状,降低机体炎症反应,有利于改善机体氧化应激状态,具有较好的临床应用价值。

Clinical study on Yuxingcao Injection combined with linezolid in treatment of pneumonia infected by methicillin resistant staphylococcus aureus

Objective To investigate the clinical efficacy of Yuxingcao Injection combined with linezolid in treatment of pneumonia infected by methicillin resistant staphylococcus aureus (MRSA). Methods Patients (78 cases) with pneumonia infected by MRSA in Zhengzhou Sixth People's Hospital from May 2014 to May 2016 were divided into control (39 cases) and treatment (319 cases) groups based on different treatments. Patients in the control group were iv administered with Linezolid Injection, 600 mg/time, twice daily. Patients in the treatment group were iv administered with Yuxingcao Injection on the basis of the control group, 100 mgL added into 5% glucose solution, once daily. Patients in two groups were treated for 2 weeks. After treatment, clinical efficacy was evaluated, and the MRSA clearance rate, relief time of clinical symptom, and serum indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 79.49% and 94.87%, respectively, and there was difference between two groups (P < 0.05). MRSA clearance rate in the control and treatment groups were 74.36% and 92.31%, respectively, and there was difference between two groups (P < 0.05). After treatment, temperature recovery time, relief time of cough, sputum, chest stufly, and polypnea in the treatment group were shorter than those in the control group, with significant difference between two groups (P < 0.05). The levels of CRP, TNF-α, PCT, and TOS in two groups were significantly decreased, but the TAS and PON1 in two groups was significantly increased, and the difference was statistically significant in the same group (P <0.05). And the serum indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Yuxingcao Injection combined with linezolid has significant effect in treatment of pneumonia infected by MRSA, can effectively improve the clinical symptoms, reduce inflammation, improve the oxidative stress state of organism, which has good clinical application value.